Ractigen Therapeutics reports study on extrahepatic delivery platform LiCO
A study published in Molecular Therapy-Nucleic Acids details the performance of Ractigen Therapeutics' LiCO platform for systemic and localized RNA delivery.
Ractigen Therapeutics has released findings from a study evaluating its LiCO delivery technology. The data, published in the journal Molecular Therapy-Nucleic Acids, shows the platform's ability to facilitate extrahepatic delivery of small activating RNAs (saRNAs) to tissues such as skeletal muscle, the heart, and adipose tissue.
The study tested both systemic and localized administration routes. Findings indicate that the platform can achieve sustained gene expression in extrahepatic sites, including the eye, joints, and bladder. By bypassing the liver, which is the primary target for many current RNA delivery systems, the technology potentially expands the range of addressable diseases.
This development marks a technical milestone for the company, as extrahepatic targeting remains a major hurdle in nucleic acid therapy development. Future clinical implications depend on the platform's ability to maintain these efficacy levels in human trials and demonstrate a favorable safety profile.